Updated antiretroviral guidelines available
The Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents were updated March 23 and are available at the AIDS info web site.
The guidelines were developed and updated by the panel on Clinical Practices for Treatment of HIV Infection, convened by the Department of Health and Human Services.
The changes in this update are outlined here:
1. "Table 12a — Antiretroviral Regimens Recommended for Treatment of HIV-1 Infection in Antiretroviral Naive Patients": Additions: 01 Fosamprenavir and ritonavir-boosted fosamprenavir to be added as part of Alternative PI-based regimens for initiation of therapy in treatment-naive patients. "Abacavir + lamivudine" has been added as an alternative 2-NRTI backbone.
Deletions: Ritonavir-boosted amprenavir has been removed as an alternative PI-based regimen for initiation of therapy in treatment naive patients. Indinavir (unboosted) has been removed as an alternative PI-based regimen for initiation of therapy in treatment-naive patients.
2. New safety information regarding the risks of nevirapine-associated symptomatic hepatic events has been added to the text of the guidelines (sections on "NNRTI-Based Regimens" and "Hepatotoxicity") and the respective tables (Tables 12a, 12b, and 19).
3. Characteristics and drug interaction information for fosamprenavir have been added to the respective tables (Tables 17, 20, 21, 22a, 22b, 23, and 30).
4. A new table (Table 13) — "Antiretroviral Dosing Recommendations for Patients with Renal or Hepatic Dysfunction" has been created.
The complete, updated adult and adolescent guidelines are available at http://AIDSinfo.nih. gov.